LXR-623 5363 is a second-generation

is a second-generation

after which the tumors are left to grow out

InChi: InChI=1S/C19H25NOS

InChi: InChI=1S/C17H17N7/c18-15-13-14(11-7-10-5-6-19-16(10)20-8-11)23-24(12-3-1-2-4-12)17(13)22-9-21-15/h5-9

Application of the nuclear factor-kappaB inhibitor Bay11-7085 for the treatment of endometriosis: an in vitro study

LXR-623 5363 is a second-generationLXR623, also known as WAY 252623, is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR( ) atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters. In nonhuman primates with normal lipid levels, WAY 252623 significantly reduced total (50 55%) and LDL cholesterol (LDLc) (70 77%) in a time and dose